COOPER COMPANIES, INC. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Cooper Companies completed its strategic review (initiated December 2025) and decided to retain CooperSurgical rather than sell it, citing temporary valuation headwinds from competitive IUD entrants and fertility litigation costs. The Board expanded the share repurchase authorization from $2 billion to $3 billion and repurchased $339.1 million (4.9 million shares at $69.16/share) in Q3 2026. Q3 revenue grew 1% organically to $1.066 billion; non-GAAP diluted EPS rose 4% to $1.15; free cash flow surged 66% to $273 million. A $307.2 million discrete tax benefit from favorable UK HMRC examination completion drove GAAP EPS to $2.24.
Why this rating
Strategic review conclusion to retain CooperSurgical is material but mixed—board rejected all bids, signaling no near-term transformation. Modest Q3 operational performance (1% organic growth, flat CooperVision) and inventory destocking headwinds partially offset by strong FCF. Buyback expansion and tax benefit are notable but don't alter fundamental trajectory.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.